Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 71610-030

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71610-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 250mg (71610 030 60)

Bottle Label 250mg (71610 030 60)
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Divalproex Sodium Structural Formula (Image 03)

Divalproex Sodium Structural Formula (Image 03)
FDA Label Image

Figure 1: Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Image 04)

Figure 1: Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Image 04)
This appears to be a chart showing the rate of reduction in CP$ (unspecified abbreviation) for patients with different degrees of improvement, no change, and worsening. The vertical axis appears to be percentage points, with improvement and worsening both labelled with arrows going up and down respectively. However, since there is no further context or explanation, the purpose and meaning of this chart cannot be determined with certainty.*
FDA Label Image

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)
This appears to be a table showing percentages of patients receiving different doses of Divalproex Sodium with delayed release. The table shows various percentages of doses ranging from low to high and indicates a higher percentage of patients with high dose Divalproex Sodium with delayed release. There also seems to be a comparison between the high dose and low dose treatments, and a notation for "No Change".*
FDA Label Image

Figure 3: Mean Reduction In 4-week Migraine Headache Rates (Image 06)

Figure 3: Mean Reduction In 4-week Migraine Headache Rates (Image 06)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.